Cat. No. | Product name | CAS No. |
DC7665 |
Gandotinib(LY2784544)
Featured
LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
1229236-86-5 |
DC7019 |
LY-2874455
Featured
LY2874455 is a novel and potent FGF/FGFR inhibitor. |
1254473-64-7 |
DC7776 |
LY-3039478
LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested. |
1421438-81-4 |
DC10640 |
LY3214996
Featured
LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. |
1951483-29-6 |
DC2018 |
LY335979 (Zosuquidar 3HCl)
Featured
LY335979 (Zosuquidar) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM. |
167465-36-3 |
DC10560 |
MAK683
Featured
MAK683 is a novel PRC2/EED inhibitor. |
1951408-58-4 |
DCAPI1146 |
Methoxsalen (Oxsoralen)
Methoxsalen (Oxsoralen) |
298-81-7 |
DC7196 |
MGCD0103 (Mocetinostat)
Featured
MGCD0103 (Mocetinostat) is a potent HDAC inhibitor with IC50 of 0.15, 0.29 and 1.66 μM for HDAC 1, HDAC 2 and HDAC 3, respectively. |
726169-73-9 |
DC8545 |
MI-503
Featured
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-MLL interaction. |
1857417-13-0 |
DC8414 |
MI-77301 (SAR405838)
Featured
MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
1303607-60-4 |
DC5086 |
Ixazomib(MLN2238)
Featured
MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. |
1072833-77-2 |
DC5176 |
Pevonedistat
Featured
MLN4924 is a small molecule inhibitor of Nedd8 activating enzyme (NAE) with IC50 of 4 nM. |
905579-51-3 |
DC5089 |
Ixazomib Citrate (MLN-9708)
Featured
MLN-9708 is a proteasome inhibitor, which inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome. |
1239908-20-3 |
DC3144 |
Nilotinib
Featured
Nilotinib (AMN-107, Tasigna) is a Bcr-Abl inhibitor with IC50 less than 30 nM. |
641571-10-0 |
DC4174 |
NVP-AEW541
Featured
NVP-AEW541 is a potent inhibitor of IGF-1R with IC50 of 86 nM. |
475489-16-8 |
DC7303 |
NVP-TAE684
Featured
NVP-TAE684(TAE684) is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM. |
761439-42-3 |
DC12281 |
Olutasidenib (FT-2102)
Featured
Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 that could be used in the treatment of acute myeloid leukemia. |
1887014-12-1 |
DC10043 |
ONO4059 hydrochloride
Featured
ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM. |
1439901-97-9 |
DC8358 |
ONO-4059(Tirabrutinib)
Featured
ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase. |
1351636-18-4 |
DC2010 |
Oprozomib (ONX-0912)
Featured
Oprozomib (ONX 0912) selectively inhibits CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. |
935888-69-0 |
DC1006 |
OSI-027
Featured
OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. |
936890-98-1 |
DC7220 |
OSU-03012
Featured
OSU-03012(AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067. |
742112-33-0 |